Modus’ largest owners are Karolinska Development (Nasdaq Stockholm: KDEV), KDev Investments AB, (jointly owned by Karolinska Development AB and Rosetta Capital) and John Öhd. The company has been listed on the Nasdaq First North Growth Market since July 2021.
Modus Therapeutics Holding
Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need. The Company’s focus is to develop sevuparin for patients with sepsis/septic shock, a severe and often fatal condition.
